Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Cash from Investing Activities (2016 - 2025)

Sangamo Therapeutics (SGMO) has 16 years of Cash from Investing Activities data on record, last reported at -$64000.0 in Q3 2025.

  • For Q3 2025, Cash from Investing Activities fell 127.47% year-over-year to -$64000.0; the TTM value through Sep 2025 reached $1.2 million, down 98.33%, while the annual FY2024 figure was $37.5 million, 75.56% down from the prior year.
  • Cash from Investing Activities reached -$64000.0 in Q3 2025 per SGMO's latest filing, down from -$24000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $89.3 million in Q2 2021 and bottomed at -$13.5 million in Q3 2022.
  • Average Cash from Investing Activities over 5 years is $27.7 million, with a median of $35.8 million recorded in 2023.
  • Peak YoY movement for Cash from Investing Activities: surged 1995.48% in 2023, then plummeted 127.47% in 2025.
  • A 5-year view of Cash from Investing Activities shows it stood at $52.6 million in 2021, then dropped by 19.04% to $42.6 million in 2022, then decreased by 11.51% to $37.7 million in 2023, then plummeted by 96.49% to $1.3 million in 2024, then crashed by 104.83% to -$64000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were -$64000.0 in Q3 2025, -$24000.0 in Q2 2025, and $1.3 million in Q4 2024.